Bioequivalence Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fasting Conditions
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To compare the single-dose oral bioavailability of clarithromycin 250-mg/5 mL powder for oral
suspension of Ranbaxy Laboratories with that of Abbott Laboratories (Biaxin®) following
administration of a 250 mg/5 mL dose in healthy, adult, human, male subjects under fasting
conditions.